China Gene Therapy Market Size & Outlook, 2023-2030
Related Markets
China gene therapy market highlights
- The China gene therapy market generated a revenue of USD 237.2 million in 2023 and is expected to reach USD 409.4 million by 2030.
- The China market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, adenovirus was the largest revenue generating vector type in 2023.
- Other Vector Type is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 237.2 million |
| Market revenue in 2030 | USD 409.4 million |
| Growth rate | 8.1% (CAGR from 2024 to 2030) |
| Largest segment | Adenovirus |
| Fastest growing segment | Other Vector Type |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Adenovirus, Other Vector Type |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, China accounted for 2.8% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 246.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Gensight Biologics SA | View profile | 46 | 74, rue du Faubourg Saint-Antoine, Paris, France, 75012 | https://www.gensight-biologics.com |
| Ultragenyx Pharmaceutical Inc | View profile | 1276 | 60 Leveroni Court, Novato, CA, United States, 94949 | https://www.ultragenyx.com |
| Regenxbio Inc | View profile | 344 | 9804 Medical Center Drive, Rockville, MD, United States, 20850 | https://www.regenxbio.com |
| Oxford Biomedical Research | View profile | 11-50 | Rochester Hills, Michigan, United States, North America | https://www.oxfordbiomed.com/ |
| Benitec Biopharma Inc | View profile | 16 | 3940 Trust Way, Hayward, CA, United States, 94545 | https://www.benitec.com |
| Transgene SA | View profile | 158 | 400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, France, 67400 | https://www.transgene.fr |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | https://www.sangamo.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | https://www.bluebirdbio.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | https://www.cellectis.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | https://www.sibiono.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | https://www.uniqure.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
China gene therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gene therapy market will help companies and investors design strategic landscapes.
Adenovirus was the largest segment with a revenue share of 62.39% in 2023. Horizon Databook has segmented the China gene therapy market based on adenovirus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
China is the first country to commercially use an approved gene therapy molecule in 2003. Gendicine and Oncorine were approved for commercial use in 2003 and 2005, respectively. These drugs were proven to be effective in the treatment of head & neck cancer and are still being used for the same.
China is also focused on the development of newer therapies, such as gene editing, to cure lung cancer. In 2016, Chinese scientists found a way to cure lung cancer by using gene-editing technology and clinical trials to test the same that was recently initiated.
The drugs were expected to reach the market during the forecast period. Furthermore, global players operating in gene therapy market are collaborating with home-grown companies to expedite their production. For instance, in March 2019, Merck KgaA collaborated with GenScript— a Chinese biotech company—for the manufacturing of plasmids and viral vectors.
Reasons to subscribe to China gene therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China gene therapy market databook
-
Our clientele includes a mix of gene therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China gene therapy market , including forecasts for subscribers. This country databook contains high-level insights into China gene therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China gene therapy market size, by vector type, 2018-2030 (US$M)
China Gene Therapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
